Compare RS & INAB Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | RS | INAB |
|---|---|---|
| Founded | 1939 | 2016 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Metal Fabrications | Biotechnology: Pharmaceutical Preparations |
| Sector | Industrials | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 19.4B | 11.8M |
| IPO Year | 1996 | 2020 |
| Metric | RS | INAB |
|---|---|---|
| Price | $392.65 | $1.10 |
| Analyst Decision | Buy | Strong Buy |
| Analyst Count | 6 | 1 |
| Target Price | ★ $358.00 | $6.00 |
| AVG Volume (30 Days) | ★ 311.3K | 59.6K |
| Earning Date | 04-22-2026 | 05-11-2026 |
| Dividend Yield | ★ 1.39% | N/A |
| EPS Growth | ★ N/A | N/A |
| EPS | ★ 5.10 | N/A |
| Revenue | ★ $14,805,900,000.00 | N/A |
| Revenue This Year | $10.16 | N/A |
| Revenue Next Year | $0.82 | N/A |
| P/E Ratio | $77.45 | ★ N/A |
| Revenue Growth | N/A | ★ N/A |
| 52 Week Low | $260.31 | $0.88 |
| 52 Week High | $433.02 | $2.73 |
| Indicator | RS | INAB |
|---|---|---|
| Relative Strength Index (RSI) | 44.13 | 46.57 |
| Support Level | $382.48 | $0.92 |
| Resistance Level | $419.83 | $1.50 |
| Average True Range (ATR) | 10.33 | 0.08 |
| MACD | -0.14 | 0.00 |
| Stochastic Oscillator | 36.96 | 39.71 |
Reliance Inc operates a network of companies providing diversified metal solutions and is the metals service center company. It distributes a full line of over 100,000 metal products, including alloy, aluminum, brass, copper, carbon steel, stainless steel, titanium and other specialty steel products. The company services more than 125,000 customers in a variety of industries, including consumer products, general manufacturing, non-residential construction, transportation, aerospace, energy, electronics and semiconductor fabrication, industrial machinery and heavy industry. It also services the auto industry, through its toll processing operations where it processes customer-owned metal for a fee.
IN8bio Inc is a clinical-stage biopharmaceutical company focused on the discovery, development and commercialization of gamma-delta T cellular therapy product candidates and gamma-delta T cell engagers (TCEs) for cancer and autoimmune diseases. Gamma-delta T cells are a specialized population of T cells that possess properties. It has conducted two primary investigator-sponsored Phase 1 clinical trials evaluating its gamma-delta T cell technologies in cancer patients, which have both completed primary enrollment. INB-100 is assessing its DeltEx Allogeneic (Allo) gamma-delta T cell therapy in adult patients with high-risk leukemias undergoing haploidentical stem cell transplantation (HSCT). It operates in a single segment.